在非小细胞肺癌中,PRMT1通过调节PKM2/PKM1比率来促进华堡效应
Lu Peng1, Yujiao Zhao2, Jiang Tan2
1The Key Laboratory of Molecular Epigenetics of Ministry of Education (MOE), Northeast Normal University, Changchun, 130024, China.
Cell death & disease
|July 15, 2024
概括
蛋白质氨酸甲基转移酶1 (PRMT1) 在非小细胞肺癌 (NSCLC) 中促进华堡效应. 用黑激素和USP7抑制剂向PRMT1显示出治疗p53缺乏NSCLC的前景.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 异常的表观遗传修饰调节了瘤细胞中的华堡效应.
- 蛋白质氨酸甲基转移酶 (PRMT) 在细胞反应中至关重要,并且在各种癌症中受到放松调节.
- 在癌症Warburg效应中PRMTs的作用仍然在很大程度上是未知的.
研究的目的:
- 研究PRMT1在调节非小细胞肺癌 (NSCLC) 华堡效应中的作用.
- 在不同的葡萄糖条件下探索PRMT1,p53和葡萄糖代谢之间的相互作用.
- 评估针对NSCLC中PRMT1的治疗潜力.
主要方法:
- 在不同的葡萄糖条件下,在NSCLC中评估PRMT1表达.
- 研究了PRMT1对PKM2/PKM1比率和通过PTBP1.1.的有氧糖解的影响.
- 研究了p53状态对PRMT1调节和降解的影响.
- 在联合治疗中评估了黑激素和USP7抑制剂 (P5091) 的疗效.
主要成果:
- 在葡萄糖充足的情况下,PRMT1的表达很高,并通过通过NSCLC在PTBP1上调PKM2/PKM1比率来促进有氧糖解.
- 在葡萄糖缺乏下,p53的激活抑制USP7,导致PRMT1降解.
- 黑色素抑制了p53野生型NSCLC的扩散;与黑色素和P5091的联合治疗增强了p53缺乏NSCLC的抗癌活性.
结论:
- 在NSCLC中,PRMT1在调节华堡效应方面发挥着重要作用.
- 向PRMT1,特别是与黑激素和USP7抑制相结合,为缺乏p53的NSCLC提供了一个有希望的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
Destabilization of Microtubules
2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K


